TSHA
Taysha Gene Therapies, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.94
+8.84%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$0.13
- Revenue estimate
- $755.6K
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.13
- EPS estimate
- -$0.11
- Revenue actual
- —
- Revenue estimate
- $680.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- -1.9%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $13
- PT range
- $13 – $13
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 11, 2026 | -$0.11 | -$0.13 | Miss -14.77% | — |
| May 6, 2026 | -$0.10 | -$0.12 | Miss -20.00% | — |
| Mar 19, 2026 | -$0.11 | -$0.08 | Beat 27.27% | $5.5M |
| Nov 4, 2025 | -$0.09 | -$0.09 | In line | — |
| Aug 12, 2025 | -$0.07 | -$0.09 | Miss -28.57% | $2.0M |
| May 15, 2025 | -$0.08 | -$0.08 | In line | $2.3M |
| Feb 26, 2025 | -$0.08 | -$0.07 | Beat 12.50% | $2.0M |
| Mar 19, 2024 | -$0.09 | $0.35 | Beat 488.89% | $3.6M |
| Nov 14, 2023 | -$0.13 | -$0.13 | In line | $4.7M |
| Aug 14, 2023 | -$0.31 | -$0.38 | Miss -22.58% | $2.4M |
| May 11, 2023 | -$0.35 | -$0.28 | Beat 20.00% | — |
| Aug 11, 2022 | -$1.05 | -$0.84 | Beat 20.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026